A medical expert warned of the side effects of the newly launched weight loss drug and advised that the drug should be taken ...

Danish Novo Nordisk launched its blockbuster treatment injection Ozempic in three forms in 0.25 mg, 0.5 mg and 1 mg in the ...

Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at INR 8,800 a month or four ...

Congress has the power to make obesity treatment and weight management accessible to the communities that need it.

Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with uncontrolled Type 2 diabetes mellitus (T2DM).

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally ...

Consumer companies are increasingly betting on the male grooming and personal care categories. Wasted digital ad spend in ...

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

According to the statement issued by Novo Nordisk, "Ozempic is now available in India as 0.25 mg, 0.5 mg and 1 mg in FlexTouch Pen - an easy-to-use, once-weekly pen device. The multiple dosing ...

Novo Nordisk, a global healthcare company, on Friday announced the launch of its once-weekly diabetes drug Ozempic® (injectable semaglutide) in India, marking a significant addition to the country’s ...

Ozempic, launched by Novo Nordisk in India at $24.35 weekly, aims to tap into the growing diabetes and obesity market. Despite competition looming with patent expiration next year, the company ...